



**PRESS RELEASE
FOR IMMEDIATE RELEASE**

**SERVIER CANADA announces the creation of a new
Centre of Excellence in Clinical Research**

Laval, September 6, 2013 – Servier Canada, the Canadian subsidiary of the Servier Research Group, the second largest French pharmaceutical company, has just begun construction of a Centre of Excellence in Clinical Research at its Laval location. The announcement was made today by Servier Canada senior's executives at the company's Laval headquarters, in the presence of Mr. Nicolas Marceau, Minister of Finance and Economy and Ms. Martine Beaugrand, Mayor of Laval.

This new 30,000 square-foot complex represents a \$16.3 million investment and received the assistance of Investissement Québec and the strategic support of Montréal International. It will house activities for the Canadian International Centre for Therapeutic Research (ICTR) and the Servier Canada National Centre for Professional Training.

The Centre's mission is to help further the design and development of ICTR clinical research in major therapeutic areas including cardiovascular disease, cancer and neuropsychiatry. This development project in Canada will require the company to hire additional staff, and a total of 38 new employees will join Servier Canada in the coming months.

Servier Canada, created in 1978, is at present the Group's 4th international subsidiary. It employs 303 people, including 161 in Québec, and has invested \$26.6 million in research or 12.8% of its revenues in 2012. Servier Canada expects to launch with three innovative products over the next three years. "The Servier Research Group is increasing its research endeavours in Canada; the level of excellence and attractiveness of the research sector, particularly in Québec, make it an ideal location to advance therapeutic innovation," commented Emmanuel Canet, President of Servier R&D.

Stressing the importance of the Life Sciences sector to the Canadian economy, Frédéric Fasano, Chief Executive Officer of Servier Canada, also a member of Montréal InVivo, added, “Health is a common issue. Our mission is to provide to the Canadian medical community and patients the best possible therapeutic solutions. In order to achieve this, we must bolster our research efforts and benefit from a health policy that promotes access to innovation.”

The Servier Research Group is an independent pharmaceutical group, with more than 22,000 employees, including 3,000 in R&D, around the world and is present in over 140 countries. Organized as a foundation and deeply committed to research, it reinvests a large portion of its sales in the research and development of innovative medications.

Media contact:

Nadine DOUCET

Servier Canada

(450) 978-9700 ext. 4225

(514) 601-4881

nadine.doucet@ca.netgrs.com

Website: www.servier.ca